Below is an alphabetical listing (by generic name) of the most common non-sterile compounds prepared by the IWK Pharmacy. This website replaces the Pocket Book of Extemporaneous Formulations last published in 2006. Compounds are provided in Adobe Acrobat PDF format.
For additional information please call (902) 470-8689 between 8 a.m. and 4 p.m., Monday to Friday.
The Dalhousie College of Pharmacy Drug Information Resources has links to many other compounding websites. Please click here for more information.
CAUTION: This information has been developed specifically for the IWK Health Centre. It is provided for informational purposes for qualified health care professionals. This material is not intended as a substitute for consulting qualified health care professionals. Patient situations will vary and some information may have become outdated as a result of more recent evidence or practice changes. The IWK Health Centre will not assume responsibility for the continued currency of the information, any errors or omissions, and/or any consequences arising from the use of the information outside of the IWK.
acetaZOLAMIDE oral suspension 25 mg/mL
allopurinol oral suspension 20 mg/mL
amiodarone oral suspension 5 mg/mL
amLODIPine oral suspension 1 mg/mL
atenolol oral syrup 2 mg/mL
azaTHIOprine oral suspension 50 mg/mL
Please refer to the D section for Dr. Brisseau’s ointment
calcium carbonate oral suspension 250 mg/mL (100mg elemental calcium per mL)
carvedilol oral suspension 1.25 mg/mL
celecoxib oral suspension 10 mg/mL
cloBAZam oral suspension 1 mg/mL
clonazePAM oral suspension 0.1 mg/mL
cloNIDine oral suspension 10 micrograms/mL (NOTE STRENGTH!)
Prednisone 5 mg/mL oral suspension
propranolol oral suspension 1 mg/mL
PUPP (Pruritic, Urticarial Papules and Plaques of Pregnancy) Cream
pyrazinamide oral suspension 100 mg/mL
pyridoxine (vitamin B6) oral suspension 25 mg/mL
Research Rounds - Anesthesia & Childbirth | April 6, 2017
Dalhousie University Health Law and Policy Seminar Series - Litigation as Regulation? A Tobacco Class Action Case Study | March 24, 2017